Shitanshu Uppal
Publications Update # 133
TED talk by Mary Ann Sieghart on closing the "authority gap" for women. Management of Rashes in Gynecology Oncology video, safe de-escalation of adjuvant therapies for early-stage POLE-mutated endometrial cancer, and pre-operative MRI is sufficient for evaluating early cervical cancer
GOG 278: Extra-fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy, for stage IA1, IA2, and IB1 cervical cancer
GYOEDU Resident: Postoperative Ileus
Publications Update # 132
Fate of the IP chemotherapy and now the HIPEC chemotherapy, Mirvetuximab + Bevacizumab in ovarian cancer, should we resect para-aortic nodes in locally advanced cervical cancer (video)
Publications Update # 131
Accuracy of sentinel node biopsy for large vulvar tumors, new European guidelines for opportunistic salpingectomy, and the high response rates of pembrolizumab plus lenvatinib for clear cell carcinoma, benefits of ultra-low-dose nivolumab, and the benefits of silence.
PEACOCC trial: Pembrolizumab in Advanced Clear Cell Cancer (Phase II)
Pembrolizumab demonstrated clinical benefit in heavily pretreated advanced CCGC with a tolerable safety profile. Further evaluation in a randomized trial is warranted.
Publications Update # 130
The influence of anxiety, search updates in GYOEDU, knowledge graph, mini-cards for publications update, opportunistic salpingectomy cost-effectiveness, ASCO guidelines - neoadjuvant chemotherapy in ovarian cancer and the futility ofmagnesium replacement
Publications Update # 129
Very low-risk cervical cancer appropriate for MIS simple hysterectomy (video), LASH trial, Pembrolizumab + Lenvatinib in Clear Cell Recurrences, cost-effective ways for genetic testing in ovarian cancer, PARP (olaparib) dose reductions and GYOEDU reminders
LARA Phase 2 - Pembrolizumab + Lenvatinib in Recurrent Gynecologic Cancers
Pembrolizumab plus lenvatinib demonstrated promising anti-tumor activity with an objective response rate of 40% at 24 weeks in patients with recurrent gynaecological clear cell carcinoma.